The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Sara A. Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Ron Bose
Consulting or Advisory Role - Genentech
Research Funding - Puma Biotechnology (Inst)
 
Maria J. de Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
Ella Evron
No Relationships to Disclose
 
Nisha Unni
Honoraria - M3
Consulting or Advisory Role - bioTheranostics; Pfizer
 
Sonya A. Reid
Honoraria - Novartis
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Gilead Sciences
Research Funding - Agendia
 
David I. Quinn
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Amgen; Merck KGaA; Oncolytics
 
Cristina Saura
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Phillips Health Works; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche
Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd'
 
Jose A. García-Sáenz
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Alejandro Martinez-Bueno
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Seagen
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD/Merck; Roche
 
Angel Guerrero
Consulting or Advisory Role - Pfizer, Astra Zeneca, Novartis, Seagen, Exac Science, Pierre-Fabre
Speakers' Bureau - Pfizer, Astra Zeneca, Novartis, Seagen, Exac Science, Lilly, Pierre-Fabre
Travel, Accommodations, Expenses - Pfizer, Astra Zeneca, Novartis, Gilead, Pierre-Fabre
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; Ipsen; Lilly; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - MSD (Inst); Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Hans Wildiers
Honoraria - MSD (Inst)
Consulting or Advisory Role - Astrazeneca (Inst); AstraZeneca (Inst); Augustine Therapeutics (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Immutep (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Parexel (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly (Inst); Gilead Sciences (Inst); Roche (Inst)
 
Georg Friedrich Bischof
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Judith D. Bebchuk
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
Lisa DeFazio Eli
Employment - Puma Biotechnology
Stock and Other Ownership Interests - Puma Biotechnology
 
David B. Solit
Stock and Other Ownership Interests - Elsie Biotechnologies; Fore Biotherapeutics; Function Oncology; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Elsie Biotechnologies; Fog Therapeutics; Fore Biotherapeutics; Function Oncology; PAIGE.AI (I); Pfizer; Pyramid Biosciences; Rain Therapeutics; Scorpion Therapeutics; Vividion Therapeutics